Nexstim (NXTMH) H1 2025 earnings summary

Executive summary

• Net sales rose 42% year-over-year to EUR 4.5 million in H1 2025, driven by strong Diagnostics and Research business growth and strategic partnerships.

• EBITDA turned positive at EUR 0.2 million, marking record profitability for two consecutive half-years.

• Signed exclusive agreement with Sinaptica Therapeutics for Alzheimer's therapy, with conditional payments up to EUR 1.5 million in 2025.

• Strengthened partnership with Brainlab AG, enhancing market reach and product development in neurotechnology.

• Focused on profitable growth, expanding partnerships, and launching the new NBS 6 system.

Financial highlights

• Revenue reached EUR 4.5 million in H1 2025, up 41.8% year-over-year; system sales increased nearly 80% to EUR 2.2 million.

• Recurring revenue grew 7.7% to EUR 2.1 million; licensing revenue was EUR 0.2 million.

• EBITDA was positive at EUR 0.2 million; operating loss narrowed to EUR -0.2 million; net loss for the period was EUR -0.3 million.

• Cash flow from operating activities was EUR 0.3 million; cash balance at period end was EUR 2.7 million.

• Gross margin remained high at 81%.

Outlook and guidance

• Net sales expected to grow and operating results to improve for full year 2025.

• No change in outlook from previous guidance.

• Strategic focus on profitable growth, minimizing future capital needs, and expanding partnerships, especially in the US.

• Plans to launch NBS 6 combination system in key markets in H2 2025, pending regulatory approvals.